CellMax Life
After years of research and clinical testing, we have developed non-invasive, accurate blood tests for early detection of cancer. By making cancer prevention routine, we enable everyone to take control of their own health. The more people take our breakthrough blood tests, the more lives we can save. Life over cancer.

CellMax Life

  • Publications
  • News Center
  • Company
  • Contact

CellMax Life, IncellDx Partner to Develop Circulating Tumor Cell Tests

by Stephen Su / Tuesday, 10 April 2018 / Published in In the News, Press Releases
Apr 10, 2018 | NEW YORK (GenomeWeb)
CellMax Life and IncellDx said today that they have signed an agreement to jointly develop and market circulating tumor cell tests across multiple solid tumors and indications, including personalized therapy selection and monitoring.

Under the agreement, CellMax will combine its technology for CTC isolation with IncellDx’s proprietary BioINK microfluidic reagents. Tests will be processed at CellMax’s CLIA lab in Sunnyvale, California and will be jointly marketed in the US by its sales force.

Additional terms of the agreement were not disclosed.

CellMax CEO Atul Sharan said in a statement that IncellDx’s reagent platform will bring “tremendous added value” to its tests. The first project will be to commercialize a blood-based PD-L1 assay based on analysis of both RNA and protein in captured CTCs, to be used in immunotherapy selection and monitoring.

The first generation of tests developed to measure PD-L1 required a biopsy sample of a patient’s tumor. Because blood-based testing is less invasive, easier, and can be performed repeatedly, it offers potential advantages over available assays.

CellMax and IncellDx intend to present performance data for their CTC-based PD-L1 test in non-small cell lung cancer at the annual meeting of the American Association for Cancer Research later this month.

According to the companies, the CellMax technology has been able to capture CTCs for PD-L1 testing in about 90 percent of patients across all stages of NSCLC, with about 50 percent testing PD-L1 positive.

  • Tweet

About Stephen Su

Product Manager @ CellMax Life

What you can read next

CellMax Life Raises $14M in Venture Funding, Launches Precision Cancer Testing Company for Early Detection & Optimal Management of Cancer
CellMax Life Announces CellMax CRC-Protect, a Multi-Biomarker Blood Test Clinically-Proven For Early Detection of Colorectal Cancer
CellMax Life Announces Genetic Cancer Risk Test for 98 Genes, 24 Hereditary Cancers

Education

  • Our Science
  • Publications
  • News Center
  • Company
  • Contact

U.S. Headquarters

1271 Oakmead Parkway Sunnyvale, CA 94085
Phone: +1 650-564-3905

Taiwan Office

18F-1, No.3, Park Street Nangang Dist., Taipei City 115, Taiwan
+886-2-26558455 (Taiwan)

  • © 2023 CellMax Life
  • All Rights Reserved
  • Terms and Conditions
  • Privacy Policy
TOP